

Is hypertension still a problem?


Ilkka Pörsti

**Faculty of Medicine and Health Technology
FI-33014 University of Tampere
Finland**

Email ilkka.porsti@tuni.fi

High blood pressure: worldwide the most significant risk factor causing deaths and disability

- 20 leading risk factors causing disability-adjusted life-years



Ranking legend

1-5	6-10	11-15
16-20	21-25	26-30
31-35	36-40	>40


Risk factor

High blood pressure


	Global	High-income Asia Pacific	Western Europe	Australasia	High-income North America	Central Europe	Southern Latin America	Eastern Europe	East Asia	Tropical Latin America	Central Latin America	Southeast Asia	Central Asia	Andean Latin America	North Africa and Middle East	Caribbean	South Asia	Oceania	Southern sub-Saharan Africa	Eastern sub-Saharan Africa	Central sub-Saharan Africa	Western sub-Saharan Africa
High blood pressure	1	1	2	3	4	1	2	2	1	2	4	1	1	2	1	1	3	6	2	6	5	6

Premature vascular ageing in CKD patients



- ~85% of CKD patients are hypertensive
- CKD patients with normal BP better preserve their GFR than hypertensive CKD patients
- Lower BP target (<130/80) is associated with better renal outcomes in patients with proteinuric CKD
- Intensive BP control lowers mortality risk among trial participants with hypertension and CKD



Volume wave, pressure wave, reflected pressure wave



Pulsatile flow in small arteries



2018 ESC/ESH Guidelines: management of hypertension

Table 23 Office blood pressure treatment target range



Age group	Office SBP treatment target ranges (mmHg)					Office DBP treatment target range (mmHg)
	Hypertension	+ Diabetes	+ CKD	+ CAD	+ Stroke ^a /TIA	
18 - 65 years	Target to 130 <i>or lower if tolerated</i> Not <120	Target to 130 <i>or lower if tolerated</i> Not <120	Target to <140 to 130 <i>if tolerated</i>	Target to 130 <i>or lower if tolerated</i> Not <120	Target to 130 <i>or lower if tolerated</i> Not <120	70–79
65 - 79 years ^b	Target to 130-139 <i>if tolerated</i>	Target to 130-139 <i>if tolerated</i>	Target to 130-139 <i>if tolerated</i>	Target to 130-139 <i>if tolerated</i>	Target to 130-139 <i>if tolerated</i>	70–79
≥80 years ^b	Target to 130-139 <i>if tolerated</i>	Target to 130-139 <i>if tolerated</i>	Target to 130-139 <i>if tolerated</i>	Target to 130-139 <i>if tolerated</i>	Target to 130-139 <i>if tolerated</i>	70–79
Office DBP treatment target range (mmHg)	70–79	70–79	70–79	70–79	70–79	

©ESC/ESH 2018

CAD = coronary artery disease; CKD = chronic kidney disease (includes diabetic and non-diabetic CKD); DBP = diastolic blood pressure; SBP = systolic blood pressure; TIA = transient ischaemic attack.

2018 ESC/ESH Guidelines: management of hypertension

Table 23 Office blood pressure treatment target range

Age group	This phenotype is more than 100 years old		Office DBP treatment target range (mmHg)
18 - 65 years			70–79
65 - 79 years ^b			70–79
≥80 years ^b			70–79
Office DBP treatment target range (mmHg)			

1896: Riva Rocci published work describing the use of sphygmomanometer in the *Gazzetta Medica di Torino*


1905: Nikolai Korotkov published work on auscultatory BP measurement (in 281 words) in *Izvestie Imp. Voennomedicinskoj Akademii* (Reports of the Imperial Military Medical Academy).

BP targets in renal patients

- **Strategies for treatment of hypertension in CKD (2018)**
 - Office SBP to 130–139 mmHg
 - Office DBP to 70-79 mmHg
- **BP goal <130/80 evidence-based in CKD (2019)**
 - Attention to measuring BP accurately, assessing patient preferences and concurrent medical conditions, and monitoring for adverse effects
- **CKD in diabetic patients, class I level A evidence (2020)**
 - Individualized treatment, SBP target <130 mmHg if tolerated, not <120 mmHg
 - Age >65 years: SBP goal 130-139 mmHg
 - DBP target <80 mmHg, not <70 mmHg


Accuracy of cuff-measured BP

SBP underestimated by 6 mmHg



Accuracy of cuff-measured BP


DBP overestimated by 6 mmHg



Accuracy of cuff-measured BP

Brachial PP underestimated by 12 mmHg

Altogether 74 studies with 3073 participants



Hypertension (elevated blood pressure (BP)) is the single largest risk factor for cardiovascular disease mortality

Non-invasive brachial (upper arm) cuff BP is the principal method for hypertension diagnosis and management

Does the cuff accurately measure BP?



For patients with **Normal BP**
<120/80 mm Hg

Reasonable confidence can be placed in cuff BP readings



For patients with **Prehypertension** ($\geq 120/80$ to $< 140/90$ mm Hg) or **Stage 1 hypertension** ($\geq 140/90$ to $< 160/100$ mm Hg)

Cuff **overestimates** diastolic BP at brachial and aortic level
Cuff **underestimates** systolic BP at brachial level
Cuff variably **under- or overestimates** SBP at the aorta

Improved accuracy is recommended





For patients with **Stage 2 hypertension**
 $\geq 160/100$ mm Hg


Reasonable confidence can be placed in cuff BP readings

Age and cuff-based blood pressure

- 31 studies with 1674 patients undergoing coronary angiography
- 22 different cuff BP devices: 19 oscillometric, 1 automated auscultation, 2 mercury sphygmomanometry
- Progressive increase in cuff pulse pressure underestimation with increasing age
- *“It is imperative that more personalized methods of BP measurement are developed”*







Upright Change in Aortic BP



- 613 subjects without medications
 - 301 men
 - 312 women
- Divided to tertiles according to the supine-to-upright change in central SBP


Upright Change in Aortic BP



- 613 subjects without medications
 - 301 men
 - 312 women

- Divided to tertiles according to the supine-to-upright change in central SBP


Control of circulation



$$\text{Blood pressure} = \text{Cardiac output} \times \text{Peripheral resistance}$$


$$\text{Hypertension} = \text{Increased CO} \text{ and/or } \text{Increased PR}$$

Cardiovascular response to upright posture




- 470 subjects
- Based on supine-to-upright changes in systemic vascular resistance (SVR) and cardiac output (CO), clustering to three phenotypes.
- Why these variables: SVR and CO are the principal determinants of blood pressure.

Cardiovascular response to upright posture: clustering to three phenotypes




- 470 subjects
- Based on supine-to-upright changes in systemic vascular resistance (SVR) and cardiac output (CO), clustering to three phenotypes.
- Why these variables: SVR and CO are the principal determinants of blood pressure.

Sustainer phenotype: highest cardiac sympathovagal balance





- “Sustainer” phenotype:
 - Lowest upright heart rate variability in HF power (lowest cardiac parasympathetic tone)
 - Increased supine and upright LF/HF ratio (sympathovagal balance)

Cardiovascular response to upright posture: associated with arterial stiffness




- In multivariate analysis, sustainer cluster, age, BMI and higher BP were explanatory factors for higher arterial stiffness

The arterial system is complex and blood flow is pulsatile




- A cohort of 92457 adults: mean resting heart rate is 65/min
- If 65/min is the mean heart rate for 24 hours, there are ~93600 systolic and diastolic blood pressure values within one day

Blood pressure in a 26-year-old woman



BP and heart rate in a 26-year-old woman



May Measurement Month 2018

- 1 504 963 individuals were screened in 89 countries
 - Mean age 45.3 years; 52.4% female
- Hypertension: SBP > 140 mmHg or DBP > 90 mmHg, or taking antihypertensive medication
- 33.4% of the individuals had hypertension
 - 59.5% were aware of their diagnosis
 - 55.3% were taking antihypertensive medication
- Hypertensive subjects
 - Of those on medication, 60.0% were controlled
 - Of all hypertensives, 33.2% were controlled

Hypertension is still a problem

- The methods to measure blood pressure are not optimal
- Low BP targets in CKD seem warranted and rational
 - Individual tailoring of treatment based on common sense is essential
 - BP measurement in the upright position provides relevant information
- CKD is associated with premature vascular ageing and hypertension is a major factor contributing to this process
 - Uncontrolled hypertension increases cardiovascular morbidity and mortality and accelerates progression to ESRD
- Intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in CKD
 - Adverse effects should be closely monitored and concurrent medical conditions taken carefully into account